Why the study?
Reasons to switch from vitamin K antagonists to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation even when time in therapeutic range is >70% warranted review.
Does switching from VKAs to NOACs improve clinical and safety outcomes in patients with non-valvular atrial fibrillation?
Does switching from VKAs to NOACs improve clinical and safety outcomes in patients with non-valvular atrial fibrillation?
Systematic switching from VKAs to NOACs is warranted in non-valvular atrial fibrillation to improve safety, particularly by reducing intracranial hemorrhage risk and preserving renal function.
Answers are grounded in this paper and cite their sources.
Supports NOAC preference in non-valvular AF for ICH reduction; leaves open optimal real-world switching strategies in high-risk patients.
Non-vitamin K oral anticoagulants (NOACs) are the first choice for prophylaxis of cardioembolism in patients with non-valvular atrial fibrillation (AF) who are anticoagulant-naïve, as well as the preferable anticoagulation strategy in those who are on vitamin K antagonists (VKAs), but with a low time in therapeutic range (TTR). Nonetheless, there are many good reasons to consider switching from VKAs to NOACs also when TTR is >70%. From the pharmacological standpoint, anticoagulation with VKAs may remain erratic even in those patients who have high TTR values, owing to the mode of action of this drug class. Furthermore, experimental data suggest that, unlike VKAs, NOACs favorably modulate the effects of factor Xa and thrombin in the cardiovascular system through the protease-activated receptor family. Clinically, the most striking advantage provided by NOACs over VKAs, irrespective of the TTR, is the substantially lower risk of intracranial hemorrhage. NOACs have also been associated with less deterioration of renal function as compared with VKAs and may confer protection against cardiovascular events not strictly related to AF, especially the acute complications of peripheral artery disease. In this narrative review, we discuss the evidence according to which it is warranted to systematically substitute NOACs for VKAs for the prevention of AF-related stroke and systemic embolism.
No takes yet. Share an insight, caveat, or question.
Botto et al. (2021) conducted a review in Non-valvular atrial fibrillation. Non-vitamin K oral anticoagulants (NOACs) vs. Vitamin K antagonists (VKAs) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: